Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Kristen Yen Sells 2,218 Shares

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Kristen Yen sold 2,218 shares of the firm's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $41.34, for a total transaction of $91,692.12. Following the sale, the insider now directly owns 23,422 shares of the company's stock, valued at approximately $968,265.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Kristen Yen also recently made the following trade(s):

• On Thursday, January 25th, Kristen Yen sold 397 shares of Soleno Therapeutics stock. The shares were sold at an average price of $48.30, for a total transaction of $19,175.10.

Soleno Therapeutics Trading Down 0.1 %

NASDAQ:SLNO traded down $0.05 during trading hours on Wednesday, reaching $41.76. The company had a trading volume of 260,649 shares, compared to its average volume of 305,632. Soleno Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $53.82. The firm's 50 day moving average price is $45.92 and its 200-day moving average price is $35.28. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -14.06 and a beta of -1.56.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.02). On average, analysts forecast that Soleno Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Oppenheimer raised their price target on shares of Soleno Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, January 2nd. Stifel Nicolaus assumed coverage on shares of Soleno Therapeutics in a research report on Tuesday, January 23rd. They issued a "buy" rating and a $63.00 target price for the company. Finally, Piper Sandler assumed coverage on shares of Soleno Therapeutics in a research report on Monday, February 5th. They issued an "overweight" rating and a $93.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $55.60.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Walleye Capital LLC purchased a new position in shares of Soleno Therapeutics during the 3rd quarter valued at $1,365,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Soleno Therapeutics during the 3rd quarter valued at $685,000. Emerald Mutual Fund Advisers Trust purchased a new position in shares of Soleno Therapeutics during the 3rd quarter valued at $5,941,000. Carlyle Group Inc. lifted its stake in shares of Soleno Therapeutics by 90.9% during the 3rd quarter. Carlyle Group Inc. now owns 2,293,562 shares of the company's stock valued at $67,431,000 after buying an additional 1,092,056 shares in the last quarter. Finally, Silverarc Capital Management LLC purchased a new position in shares of Soleno Therapeutics during the 3rd quarter valued at $10,919,000. Hedge funds and other institutional investors own 97.42% of the company's stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.